Analgesic Comparison for Severe Burn Patients

Clinical data were obtained from the patient’s medical records from Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital. Ethical approval was obtained from the independent ethics committee of Shanghai Ruijin Hospital affiliated with Shanghai Jiao Tong University, School of Medicine (2018-14). All 76 patients after severe burns (> 70% total body surface area (TBSA)) from January 1, 2017, to December 31, 2019, were collected. Patients with incomplete information, younger than 14 years, patients who were not admitted to the hospital on the day of the injury, or whose hospital stay was less than seven days were excluded (n = 25). Finally, 51 patients were included and analyzed in this study. The patients were divided into two groups according to the treatments they received: the Fen+Mid group (fentanyl + midazolam, n = 30) and the Pet+Pro group (pethidine + promethazine, n=21). Informed consent was not required owing to the retrospective nature of the study and anonymized patient records. Patient information is summarized in Table 1.